SCHEMBL2118290

SCHEMBL2118290

Cc1[nH]c(C=C2C(=O)Nc3ccc(Br)cc32)c(-c2ccccc2)c1C(=O)NCCN1CCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 9/20 0.66
KDR P35968 9/20 0.66
FGFR1 P11362 6/20 0.66
TLK2 Q86UE8 2/20 0.66
EGFR P00533 1/20 0.58
MET P08581 1/20 0.52
FLT3 P36888 1/20 0.52
AURKB Q96GD4 1/20 0.52
PRKAA2 P54646 4/20 0.50
PRKAA1 Q13131 4/20 0.50
PIM1 P11309 4/20 0.49
PIM2 Q9P1W9 3/20 0.49
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31672415 1.00 PDGFRB (0.66) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL13755205 1.00 PDGFRB (0.66) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL13755224 0.89 PDGFRB (0.81) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL31672474 0.89 PDGFRB (0.81) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL2117954 0.89 PDGFRB (0.81) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL2114270 0.86 PDGFRB (0.51) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL31672426 0.86 PDGFRB (0.51) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL13755196 0.86 PDGFRB (0.51) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL2113951 0.86 KDR (0.67) PDGFRBKDRFGFR1TLK2EGFR
SCHEMBL13755198 0.86 KDR (0.67) PDGFRBKDRFGFR1TLK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates PTK2B, ERBB2, FRK PDGFRB 555/4885KDR 395/4885FGFR1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.